Zurich Cantonal Bank
AVBP icon

Zurich Cantonal Bank’s ArriVent BioPharma AVBP Stock Holding History

Zurich Cantonal Bank’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,743
Closed -$95.4K – 3430
2025
Q4 		$95.4K Buy
+4,743
New +$98.7K ﹤0.01% 2395

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Zurich Cantonal Bank's AVBP Position: Q2 2026 in Review

Zurich Cantonal Bank increased its ArriVent BioPharma (AVBP) stake by 116% in Q2 2026, buying an estimated $448K and bringing the position to 28,283 shares worth $983K. The position accounts for ﹤0.01% of the portfolio, ranked #1564.

Zurich Cantonal Bank first reported a position in AVBP in Q1 2025 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Zurich Cantonal Bank held 28,283 shares of ArriVent BioPharma worth $983K as of Q2 2026.
  • Zurich Cantonal Bank bought 15,177 ArriVent BioPharma shares in Q2 2026, an estimated $448K.
  • ArriVent BioPharma made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1564 holding.
  • Zurich Cantonal Bank first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.